Verona Pharma PLC ADR - Asset Resilience Ratio
Verona Pharma PLC ADR (VRNA) has an Asset Resilience Ratio of 0.00% as of September 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See VRNA working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2020)
This chart shows how Verona Pharma PLC ADR's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see VRNA total asset value.
Liquid Assets Composition Over Time
This chart breaks down Verona Pharma PLC ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore VRNA strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Verona Pharma PLC ADR maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Verona Pharma PLC ADR Industry Peers by Asset Resilience Ratio
Compare Verona Pharma PLC ADR's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Verona Pharma PLC ADR (2006–2020)
The table below shows the annual Asset Resilience Ratio data for Verona Pharma PLC ADR.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2020-12-31 | 5.02% | $10.26 Million | $204.21 Million | -12.31pp |
| 2019-12-31 | 17.33% | $10.26 Million | $59.18 Million | -43.16pp |
| 2018-12-31 | 60.49% | $57.00 Million | $94.23 Million | +5.94pp |
| 2017-12-31 | 54.54% | $65.97 Million | $120.96 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $56.93 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $10.96 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $20.43 Million | -- |
| 2006-12-31 | 32.80% | $2.55 Million | $7.77 Million | -- |
About Verona Pharma PLC ADR
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pu… Read more